| 1. |
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage Ⅲ melanoma with Ipilimumab adjuvant therapy[J]. N Engl J Med, 2016, 375(19): 1845-1855. DOI: 10.1056/NEJMoa 1611299.
|
| 2. |
Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2020, 6(3): 375-384. DOI: 10.1001/jamaoncol.2019.5367.
|
| 3. |
Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016, 13(8): 473-486. DOI: 10.1038/nrclinonc.2016.58.
|
| 4. |
Bomze D, Meirson T, Hasan Ali O, et al. Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis[J]. Ocul Immunol Inflamm, 2022, 30(1): 191-197. DOI: 10.1080/09273948.2020.1773867.
|
| 5. |
Yilmaz T B, Ozkan B, Sonmez O. Recurrent episodes with serous retinal detachment and anterior uveitis in a patient using Nivolumab (anti-PD-1 antibody) therapy: a case report and literature review[J]. Semin Ophthalmol, 2021, 36(8): 794-799. DOI: 10.1080/08820538.2021.1906916.
|
| 6. |
Young L, Finnigan S, Streicher H, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors[J/OL]. J Immunother Cancer, 2021, 9(7): e002119[2021-07-01]. https://pubmed.ncbi.nlm.nih.gov/34226280/. DOI: 10.1136/jitc-2020-002119.
|
| 7. |
Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes[J]. Ocul Immunol Inflamm, 2021, 29(1): 203-211. DOI: 10.1080/09273948.2020.1781902.
|
| 8. |
Bricout M, Petre A, Amini-Adle M, et al. Vogt-Koyanagi-Harada-like syndrome complicating Pembrolizumab treatment for metastatic melanoma[J]. J Immunother, 2017, 40(2): 77-82. DOI: 10.1097/CJI.0000000000000154.
|
| 9. |
Crosson JN, Laird PW, Debiec M, et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma[J]. J Immunother, 2015, 38(2): 80-84. DOI: 10.1097/CJI.0000000000000066.
|
| 10. |
Cunningham ET, Moorthy RS, Zierhut M. Immune checkpoint inhibitor-induced uveitis[J]. Ocul Immunol Inflamm, 2020, 28(6): 847-849. DOI: 10.1080/09273948.2020.1801286.
|
| 11. |
Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Vogt-Koyanagi-Harada disease[J]. Am J Ophthalmol, 2021, 228: 205-211. DOI: 10.1016/j.ajo.2021.03.036.
|
| 12. |
Conrady CD, Larochelle M, Pecen P, et al. Checkpoint inhibitor-induced uveitis: a case series[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(1): 187-191. DOI: 10.1007/s00417-017-3835-2.
|
| 13. |
Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report[J]. BMC Ophthalmol, 2020, 20(1): 252. DOI: 10.1186/s12886-020-01519-5.
|
